Technology
Health
Biotechnology

Axovant Gene Therapies

$6.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-6.56%) Today
+$0.10 (1.56%) After Hours

Why Robinhood?

You can buy or sell AXGT and other stocks, options, ETFs, and crypto commission-free!

About

Axovant Gene Therapies Ltd. Common Shares, also called Axovant Gene Therapies, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Read More Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.

Employees
57
Headquarters
London, London & South East
Founded
2014
Market Cap
156.27M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
297.13K
High Today
$6.65
Low Today
$6.00
Open Price
$6.50
Volume
1.18M
52 Week High
$24.32
52 Week Low
$3.81

Collections

Technology
Health
Biotechnology
Gene Therapies
Medical
Biopharmaceutical
Therapy
Pharmaceutical

Earnings

-$0.64
-$0.49
-$0.33
-$0.18
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
-$0.45 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.